obesity drug news today glp-1 2025 Use of diabetes and anti-obesity drugs surges nationwide GLP-1 Pharmacy Pricing Update (Dec

Nat Commun 15 , 5912 (2024)

Despite the potential of GLP-1RA plus SGLT2i combination therapy to improve metabolic-cardiovascular-renal trajectories, several factors may delay this combination to become a common practice soon, and most T2DM patients with ASCVD or at high ASCVD risk remain inadequately managed

This leads to increased urinary glucose excretion

The twist is that a subset of gut bacteria can chew on L-carnitine and related nutrients and make a small volatile compound called trimethylamine or TMA

This is not a flaw

This strongly suggests that the metabolic shock of rapid dose escalation, not the medication dose itself, drives most fatigue complaints